Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Mental Disease

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400735

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1400735

Psychedelic API Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

PUBLISHED:
PAGES: 361 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global Psychedelic API (Active Pharmaceutical Ingredient) Market is experiencing unprecedented growth, with its valuation reaching US$ 1.9 billion in 2024. Projections indicate that the market to reach a valuation of US$ 5.7 billion by the end of 2031.

Psychedelics, substances derived primarily from fungi, notably mushrooms, have been employed as medicines for thousands of years. In recent times, there has been a growing interest in the use of psychedelics and other fungal active substances to treat various mental health conditions, including anxiety, addiction, and major depressive disorder. These substances, known for their anti-addictive, anxiolytic, and antidepressant properties, have garnered attention and spurred neuropharmacological research.

Key drivers of the Psychedelic API Market's growth include:

1. Advancements in Therapeutic Use: The potential of substances like lysergic acid diethylamide (LSD), psilocybin, and others to provide therapeutic options, particularly for treatment-resistant patients, is driving market expansion.

2. Regulatory Shifts: Changing regulations and increased acceptance of formerly prohibited substances for medical applications have opened doors for entrepreneurs and venture capital firms, resulting in substantial funding for psychedelic therapies.

3. Contract Manufacturing Opportunities: Contract Manufacturing Organizations (CMOs) are poised to play a crucial role in making regulated medications accessible, offering opportunities for small-cap pharmaceutical companies.

However, several challenges might affect market growth, including:

1. High Production Costs: Extracting active ingredients from complex organic sources can be expensive and technically challenging.

2. Patient Scalability Issues: Once licensed, previously stigmatized medications may face challenges in achieving broad patient scalability, particularly when combined with psychotherapy, which is often required for maximum effectiveness.

Why the United States Market is Booming:

The United States has seen substantial growth in the Psychedelic API Market due to regulatory changes and increased research efforts on psychedelics. Regulatory oversight is critical for ensuring safe and effective use of these substances.

United Kingdom as a Lucrative Market:

The UK holds potential as a lucrative market, but it requires revised regulations to fully harness the therapeutic potential of psilocybin research.

China's Emergence as a Prominent Market:

China is becoming a prominent player in the Psychedelic API industry, with an increasing focus on Contract Manufacturing Organizations (CMOs) and adherence to cGMP (current Good Manufacturing Practices) standards.

Competitive Landscape:

Companies in the industry are focusing on providing a wide range of APIs and participating in the development of new psychedelic drugs. Venture capital firms are also actively investing in start-ups working on psychedelic medicines.

Key Companies Profiled:

  • Core One Labs Inc.
  • Cayman Chemical Company (Matreya)
  • COMPASS Pathways plc
  • Beckley Psytech
  • Atai Life Sciences
  • Tryp Therapeutics
  • Filament Health
  • Ceruvia Lifesciences, LLC
  • BetterLife Pharma
  • Psygen Pharmaceutical
  • Mindset Pharma

Market Segmentation

Product:

  • API-Grade Psilocybin
  • API-Grade DMT
  • LSD API
  • MDMA API
  • Ketamine API
  • Others

API Compound:

  • Active Plant Components
  • Novel Synthetic Compounds
  • Metabolites
  • Isotopically Labelled Standards

Source:

  • Natural
  • Synthetic
  • Bio-Synthetic

Grade:

  • GMP
  • Non-GMP

Application:

  • Clinical
  • Research

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Psychedelic API Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Psychedelic API Market Outlook, 2018 - 2031

  • 3.1. Global Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. API-Grade Psilocybin
      • 3.1.1.2. API-Grade DMT
      • 3.1.1.3. LSD API
      • 3.1.1.4. MDMA API
      • 3.1.1.5. Ketamine API
      • 3.1.1.6. Others
  • 3.2. Global Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Active Plant Components
      • 3.2.1.2. Novel Synthetic Compounds
      • 3.2.1.3. Metabolites
      • 3.2.1.4. Isotopically Labelled Standards
  • 3.3. Global Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Natural
      • 3.3.1.2. Synthetic
      • 3.3.1.3. Bio-Synthetic
  • 3.4. Global Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. GMP
      • 3.4.1.2. Non-GMP
      • 3.4.1.3. Others
  • 3.5. Global Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. Clinical
      • 3.5.1.2. Research
  • 3.6. Global Psychedelic API Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.6.1. Key Highlights
      • 3.6.1.1. North America
      • 3.6.1.2. Europe
      • 3.6.1.3. Asia Pacific
      • 3.6.1.4. Latin America
      • 3.6.1.5. Middle East & Africa

4. North America Psychedelic API Market Outlook, 2018 - 2031

  • 4.1. North America Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. API-Grade Psilocybin
      • 4.1.1.2. API-Grade DMT
      • 4.1.1.3. LSD API
      • 4.1.1.4. MDMA API
      • 4.1.1.5. Ketamine API
      • 4.1.1.6. Others
  • 4.2. North America Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Active Plant Components
      • 4.2.1.2. Novel Synthetic Compounds
      • 4.2.1.3. Metabolites
      • 4.2.1.4. Isotopically Labelled Standards
  • 4.3. North America Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Natural
      • 4.3.1.2. Synthetic
      • 4.3.1.3. Bio-Synthetic
  • 4.4. North America Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. GMP
      • 4.4.1.2. Non-GMP
      • 4.4.1.3. Others
  • 4.5. North America Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. Clinical
      • 4.5.1.2. Research
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis
  • 4.6. North America Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.6.1. Key Highlights
      • 4.6.1.1. U.S. Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.6.1.2. U.S. Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 4.6.1.3. U.S. Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 4.6.1.4. U.S. Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 4.6.1.5. U.S. Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 4.6.1.6. Canada Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 4.6.1.7. Canada Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 4.6.1.8. Canada Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 4.6.1.9. Canada Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 4.6.1.10. Canada Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
    • 4.6.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Psychedelic API Market Outlook, 2018 - 2031

  • 5.1. Europe Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. API-Grade Psilocybin
      • 5.1.1.2. API-Grade DMT
      • 5.1.1.3. LSD API
      • 5.1.1.4. MDMA API
      • 5.1.1.5. Ketamine API
      • 5.1.1.6. Others
  • 5.2. Europe Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Active Plant Components
      • 5.2.1.2. Novel Synthetic Compounds
      • 5.2.1.3. Metabolites
      • 5.2.1.4. Isotopically Labelled Standards
  • 5.3. Europe Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Natural
      • 5.3.1.2. Synthetic
      • 5.3.1.3. Bio-Synthetic
  • 5.4. Europe Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. GMP
      • 5.4.1.2. Non-GMP
      • 5.4.1.3. Others
  • 5.5. Europe Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Clinical
      • 5.5.1.2. Research
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis
  • 5.6. Europe Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.6.1. Key Highlights
      • 5.6.1.1. Germany Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.6.1.2. Germany Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 5.6.1.3. Germany Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 5.6.1.4. Germany Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 5.6.1.5. Germany Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.6.1.6. U.K. Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.6.1.7. U.K. Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 5.6.1.8. U.K. Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 5.6.1.9. U.K. Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 5.6.1.10. U.K. Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.6.1.11. France Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.6.1.12. France Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 5.6.1.13. France Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 5.6.1.14. France Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 5.6.1.15. France Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.6.1.16. Italy Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.6.1.17. Italy Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 5.6.1.18. Italy Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 5.6.1.19. Italy Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 5.6.1.20. Italy Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.6.1.21. Turkey Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.6.1.22. Turkey Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 5.6.1.23. Turkey Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 5.6.1.24. Turkey Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 5.6.1.25. Turkey Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.6.1.26. Russia Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.6.1.27. Russia Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 5.6.1.28. Russia Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 5.6.1.29. Russia Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 5.6.1.30. Russia Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 5.6.1.31. Rest of Europe Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 5.6.1.32. Rest of Europe Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 5.6.1.33. Rest of Europe Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 5.6.1.34. Rest of Europe Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 5.6.1.35. Rest of Europe Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
    • 5.6.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Psychedelic API Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. API-Grade Psilocybin
      • 6.1.1.2. API-Grade DMT
      • 6.1.1.3. LSD API
      • 6.1.1.4. MDMA API
      • 6.1.1.5. Ketamine API
      • 6.1.1.6. Others
  • 6.2. Asia Pacific Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Active Plant Components
      • 6.2.1.2. Novel Synthetic Compounds
      • 6.2.1.3. Metabolites
      • 6.2.1.4. Isotopically Labelled Standards
  • 6.3. Asia Pacific Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Natural
      • 6.3.1.2. Synthetic
      • 6.3.1.3. Bio-Synthetic
  • 6.4. Asia Pacific Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. GMP
      • 6.4.1.2. Non-GMP
      • 6.4.1.3. Others
  • 6.5. Asia Pacific Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. Clinical
      • 6.5.1.2. Research
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis
  • 6.6. Asia Pacific Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.6.1. Key Highlights
      • 6.6.1.1. China Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.6.1.2. China Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 6.6.1.3. China Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 6.6.1.4. China Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 6.6.1.5. China Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.6.1.6. Japan Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.6.1.7. Japan Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 6.6.1.8. Japan Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 6.6.1.9. Japan Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 6.6.1.10. Japan Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.6.1.11. South Korea Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.6.1.12. South Korea Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 6.6.1.13. South Korea Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 6.6.1.14. South Korea Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 6.6.1.15. South Korea Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.6.1.16. India Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.6.1.17. India Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 6.6.1.18. India Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 6.6.1.19. India Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 6.6.1.20. India Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.6.1.21. Southeast Asia Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.6.1.22. Southeast Asia Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 6.6.1.23. Southeast Asia Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 6.6.1.24. Southeast Asia Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 6.6.1.25. Southeast Asia Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 6.6.1.26. Rest of Asia Pacific Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 6.6.1.27. Rest of Asia Pacific Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 6.6.1.28. Rest of Asia Pacific Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 6.6.1.29. Rest of Asia Pacific Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 6.6.1.30. Rest of Asia Pacific Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
    • 6.6.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Psychedelic API Market Outlook, 2018 - 2031

  • 7.1. Latin America Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. API-Grade Psilocybin
      • 7.1.1.2. API-Grade DMT
      • 7.1.1.3. LSD API
      • 7.1.1.4. MDMA API
      • 7.1.1.5. Ketamine API
      • 7.1.1.6. Others
  • 7.2. Latin America Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Active Plant Components
      • 7.2.1.2. Novel Synthetic Compounds
      • 7.2.1.3. Metabolites
      • 7.2.1.4. Isotopically Labelled Standards
  • 7.3. Latin America Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Natural
      • 7.3.1.2. Synthetic
      • 7.3.1.3. Bio-Synthetic
  • 7.4. Latin America Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. GMP
      • 7.4.1.2. Non-GMP
      • 7.4.1.3. Others
  • 7.5. Latin America Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Clinical
      • 7.5.1.2. Research
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis
  • 7.6. Latin America Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.6.1. Key Highlights
      • 7.6.1.1. Brazil Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.6.1.2. Brazil Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 7.6.1.3. Brazil Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 7.6.1.4. Brazil Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 7.6.1.5. Brazil Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.6.1.6. Mexico Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.6.1.7. Mexico Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 7.6.1.8. Mexico Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 7.6.1.9. Mexico Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 7.6.1.10. Mexico Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.6.1.11. Argentina Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.6.1.12. Argentina Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 7.6.1.13. Argentina Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 7.6.1.14. Argentina Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 7.6.1.15. Argentina Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 7.6.1.16. Rest of Latin America Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 7.6.1.17. Rest of Latin America Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 7.6.1.18. Rest of Latin America Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 7.6.1.19. Rest of Latin America Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 7.6.1.20. Rest of Latin America Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
    • 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Psychedelic API Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Psychedelic API Market Outlook, by Product, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. API-Grade Psilocybin
      • 8.1.1.2. API-Grade DMT
      • 8.1.1.3. LSD API
      • 8.1.1.4. MDMA API
      • 8.1.1.5. Ketamine API
      • 8.1.1.6. Others
  • 8.2. Middle East & Africa Psychedelic API Market Outlook, by API Compound, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Active Plant Components
      • 8.2.1.2. Novel Synthetic Compounds
      • 8.2.1.3. Metabolites
      • 8.2.1.4. Isotopically Labelled Standards
  • 8.3. Middle East & Africa Psychedelic API Market Outlook, by Source, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Natural
      • 8.3.1.2. Synthetic
      • 8.3.1.3. Bio-Synthetic
  • 8.4. Middle East & Africa Psychedelic API Market Outlook, by Grade, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GMP
      • 8.4.1.2. Non-GMP
      • 8.4.1.3. Others
  • 8.5. Middle East & Africa Psychedelic API Market Outlook, by Application, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. Clinical
      • 8.5.1.2. Research
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis
  • 8.6. Middle East & Africa Psychedelic API Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.6.1. Key Highlights
      • 8.6.1.1. GCC Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.6.1.2. GCC Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 8.6.1.3. GCC Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 8.6.1.4. GCC Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 8.6.1.5. GCC Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.6.1.6. South Africa Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.6.1.7. South Africa Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 8.6.1.8. South Africa Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 8.6.1.9. South Africa Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 8.6.1.10. South Africa Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.6.1.11. Egypt Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.6.1.12. Egypt Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 8.6.1.13. Egypt Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 8.6.1.14. Egypt Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 8.6.1.15. Egypt Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.6.1.16. Nigeria Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.6.1.17. Nigeria Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 8.6.1.18. Nigeria Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 8.6.1.19. Nigeria Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 8.6.1.20. Nigeria Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
      • 8.6.1.21. Rest of Middle East & Africa Psychedelic API Market by Product, Value (US$ Bn), 2018 - 2031
      • 8.6.1.22. Rest of Middle East & Africa Psychedelic API Market by API Compound, Value (US$ Bn), 2018 - 2031
      • 8.6.1.23. Rest of Middle East & Africa Psychedelic API Market by Source, Value (US$ Bn), 2018 - 2031
      • 8.6.1.24. Rest of Middle East & Africa Psychedelic API Market by Grade, Value (US$ Bn), 2018 - 2031
      • 8.6.1.25. Rest of Middle East & Africa Psychedelic API Market by Application, Value (US$ Bn), 2018 - 2031
    • 8.6.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Source vs by API Compound Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. Core One Labs Inc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Cayman Chemical Company (Matreya)
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. COMPASS Pathways plc
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Beckley Psytech
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Atai Life Sciences
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Tryp Therapeutics
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Filament Health
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Ceruvia Lifesciences, LLC
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. BetterLife Pharma
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Psygen Pharmaceutical
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Mindset Pharma
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!